Clinical trial
The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation…
NCT00343499 · Intermountain Health Care, Inc., Other · Terminated
Key facts
| NCT number | NCT00343499 |
|---|---|
| Title | The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial) |
| Official title | A Single Center, Randomized Trial to Evaluate the Effects of Diovan to Maintain Sinus Rhythm in Patients With Persistent Atrial Fibrillation |
| Lead sponsor | Intermountain Health Care, Inc., Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | valsartan |
| Enrollment | 200 |
| Start date | Nov 1, 2004 |
| Completion | Jul 1, 2007 |
| First posted | Jun 23, 2006 |
| Last update posted | Aug 21, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: